SNMMI meeting offers a special focus on radium-223 dichloride

05/21/2013 | MolecularImaging.net

A number of education sessions at this year's SNMMI Annual Meeting will focus on the newly approved radium-223 dichloride, a targeted radioisotope therapy for castrate-resistant prostate cancer, writes SNMMI Outreach Committee Co-chair Dr. Andrei Iagaru. "This is an exciting time for nuclear medicine as alpha radiation is not routinely used as a treatment. Preliminary results are encouraging and many [patient] and referring physician organizations have expressed interest in the new therapy," Iagaru writes.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA